Results of the EMPA-REG OUTCOME trial have shown that the SGLT2-inhibitor empagliflozin has met the primary cardiovascular (CV) outcomes endpoint and demonstrated superiority, reducing the risk of myocardial infarction, stroke, and CV death in more than 7000 adults with type 2 diabetes at high CV risk.
Patients in the study were given either low- or high-dose empagliflozin or placebo in combination with standard treatment (eg, glucose-lowering, lipid-lowering, and antihypertensive agents). Body weight and blood pressure also decreased modestly.
Empagliflozin was approved by the FDA last year and is the first glucose-lowering agent to demonstrate CV risk reduction in a CV outcomes trial. Full study results are expected to be presented in September.
To hear expert perspective on the topic, a CME symposium titled “A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care” will be held at #CMHC2015 on Thursday, October 22. Jay S. Skyler, MD will chair the symposium accompanied by faculty Deepak L. Bhatt, MD, MPH, Jennifer B. Green, MD, and Darren K. McGuire, MD, MHSc.
Read more here.